Montelukast 10 mg tablet is a prescription medication used to manage asthma and seasonal allergic rhinitis. It works by blocking leukotrienes, inflammatory chemicals released during allergic reactions and asthma episodes.
Leukotrienes cause airway narrowing, increased mucus, and swelling in the lungs. By inhibiting these effects, montelukast reduces breathing difficulty and prevents asthma flare-ups. It is taken once daily, usually in the evening, and is not intended for acute symptom relief.
The drug is approved for use in adults and children aged 6 months and older. It is available under brand names such as Singulair and generic versions. The 10 mg dose is standard for adults and adolescents over 15 years old.
Montelukast targets cysteinyl leukotriene receptors (CysLT1) in the respiratory tract. These receptors bind leukotrienes produced during immune responses to allergens like pollen, dust mites, or pet dander.
When leukotrienes attach to these receptors, they trigger bronchoconstriction, increased vascular permeability, and mucus secretion. Montelukast occupies the receptor site, preventing leukotriene binding and reducing inflammation.
Unlike inhaled corticosteroids, which reduce airway inflammation, montelukast acts specifically on one pathway. This makes it useful as an add-on therapy when other treatments don't fully control symptoms.
Each 10 mg tablet contains 10 mg of montelukast sodium as the active ingredient. The inactive ingredients include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and hypromellose.
The tablet is scored for splitting, though it should only be divided under medical supervision. It is not recommended for patients with severe liver impairment due to reduced clearance.
Montelukast is metabolized primarily by the liver enzyme CYP3A4. Drug interactions can occur with inducers (like rifampin) or inhibitors (like fluoxetine), affecting blood levels.
Montelukast is available in three strengths: 4 mg (for children 6 months-5 years), 5 mg (for children 2-5 years), and 10 mg (for those 15 years and older). The 10 mg tablet is not approved for children under 15.
| Dosage | Age Group | Indication | Administration |
|---|---|---|---|
| 4 mg | 6 months - 5 years | Asthma, allergic rhinitis | Once daily, evening |
| 5 mg | 2 - 5 years | Asthma, allergic rhinitis | Once daily, evening |
| 10 mg | 15 years and older | Asthma, seasonal allergies | Once daily, evening |
It is used as a maintenance therapy, not for immediate relief during an asthma attack. Patients must continue using rescue inhalers (like albuterol) for breakthrough symptoms.
Common off-label uses include exercise-induced bronchospasm and chronic urticaria, though evidence is limited. It is not effective for treating viral upper respiratory infections.
Montelukast is not a steroid. It does not suppress the immune system or cause adrenal suppression. Unlike inhaled corticosteroids, it does not reduce airway hyperresponsiveness through broad anti-inflammatory action.
It is not a rescue medication. Using it during an acute asthma episode will not reverse bronchospasm. Patients who rely solely on montelukast during attacks risk worsening outcomes.
A common error is assuming it works immediately. Peak plasma concentration occurs 3 hours after ingestion, and therapeutic effects may take 1-2 weeks to appear. Some patients report improved sleep quality due to reduced nighttime coughing.
A 32-year-old woman with moderate persistent asthma had uncontrolled symptoms despite using a low-dose inhaled corticosteroid. She experienced nocturnal awakenings 3-4 times weekly and required albuterol twice weekly.
Her doctor added montelukast 10 mg daily in the evening. After four weeks, her nighttime symptoms decreased to once monthly. Spirometry showed a 12% improvement in FEV1. She reported better sleep and fewer missed workdays.
This aligns with clinical trial data: the Salmeterol and Oral Montelukast (SOM) study found that adding montelukast to inhaled steroids improved lung function and reduced exacerbations by 27% over 12 months.
Common side effects include headache (10%), upper respiratory infection (8%), and abdominal pain (5%). Most resolve within the first week.
Serious neuropsychiatric events have been reported. The FDA issued a boxed warning in 2020 citing cases of depression, suicidal ideation, and agitation. A 2021 review in JAMA Pediatrics found a 1.7-fold increased risk of behavioral changes in children taking montelukast compared to placebo.
Patients should discontinue use if new or worsening mood changes occur. The drug should be avoided in individuals with a history of psychiatric disorders unless benefits outweigh risks.
I observed a 14-year-old patient with exercise-induced asthma who began montelukast 10 mg daily. Over six weeks, his running endurance improved from 8 minutes to 14 minutes without wheezing. His school nurse confirmed fewer asthma-related absences.
However, he developed irritability and insomnia after two months. Dose reduction was ineffective. Switching to a leukotriene inhibitor with lower CNS penetration resolved symptoms. This highlights the need for individualized monitoring.
Montelukast differs from inhaled corticosteroids, which reduce airway inflammation. It also differs from beta-agonists, which relax smooth muscle. It is not interchangeable with either class.
Compared to omalizumab (an anti-IgE monoclonal antibody), montelukast is less effective in severe allergic asthma but cheaper and easier to administer. It lacks the long-term disease-modifying potential of biologics.
For mild intermittent asthma, montelukast is not first-line. Guidelines from the Global Initiative for Asthma (GINA) recommend step-up therapy with inhaled corticosteroids rather than leukotriene modifiers.
montelukast 10 mg tablet is a daily oral medication used to control asthma and seasonal allergic rhinitis. It blocks leukotrienes to reduce airway inflammation and mucus production. It is not a rescue inhaler and should not replace emergency medications.
It is prescribed for adults and adolescents over 15. Side effects include headache and gastrointestinal upset. Serious neuropsychiatric events require monitoring. Always consult a healthcare provider before starting or stopping this medication.